Oncotelic completes Tranche 3 of unit offering, raising $1.1M from 22 investors

Oncotelic Therapeutics, Inc.

Issued 44 units under final Tranche 3; each unit includes a $25,000 principal, 12% 2-year convertible note.
Each note convertible into 250,000 shares of Oncotelic at $0.10 or 25,000 EdgePoint shares at $1.00.
Each unit includes 250,000 warrants to purchase Oncotelic stock at $0.12 or EdgePoint warrants at $1.25.
Prior 2023 PPM notes settled; existing warrants extended to two years from final closing.
Registration Rights Agreement executed for shares and warrants issued in the financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.